The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Immune Regulation of Cancer
Open accessAbstract
Innate and adaptive immune system cells play a major role in regulating the growth of cancer. Although it is commonly thought that an immune response localized to the tumor will inhibit cancer growth, it is clear that some types of inflammation induced in a tumor may also lead to cancer proliferation, invasion, and dissemination. Recent evidence suggests, however, that some patients with cancer can mount an antitumor immune response that has the potential to control or eliminate cancer. Indeed, a so-called “immune response” signature has been described in malignancy that is associated with improved outcomes in several tumor types. Moreover, the presence of specific subsets of T cells, which have the capability to penetrate tumor stroma and infiltrate deep into the parenchyma, identifies patients with an improved prognosis. Immune-based therapies have the potential to modulate the tumor microenvironment by eliciting immune system cells that will initiate acute inflammation that leads to tissue destruction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“The importance of intratumoral T cells in prognosis was further underscored in a study that evaluated immune infiltrates in patients with ovarian cancer.(28) One of the first studies to identify the location of infiltrating T cells in relation to the tumor as important, its results demonstrated that patients with intr…”
ResultCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“The clinical efficacy of monoclonal antibody therapy with agents such as trastuzumab and rituxan is likely due, in part, to immune-mediated mechanisms.(63) A common theme relevant to the success of these approaches is that they are generally used when malignancies are at a low burden of disease and/or noninvasive.”
BackgroundEffector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“A similar study, performed in colon cancer, confirmed and extended these observations by further phenotyping the intratumoral T cells.(29) Investigators demonstrated that high levels of intratumoral CD45RO (memory) T cells correlated with better survival.”
ResultKirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Cited by
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
The complexity of NF-κB signaling in inflammation and cancer
Hoesel, B., & Schmid, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-86 · Cited by 3,165
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Cancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
Role of sleep deprivation in immune-related disease risk and outcomes
Garbarino, S., Lanteri, P., Bragazzi, N. L., Magnavita, N., & Scoditti, E. (2021) · Communications Biology · doi:10.1038/s42003-021-02825-4 · Cited by 571
Martinet, L., Garrido, I., Filleron, T., Le Guellec, S., Bellard, E., Fournie, J.-J., Rochaix, P., & Girard, J.-P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0431 · Cited by 516
NF-κB in inflammation and cancer
Mao, H., Zhao, X., & Sun, S.-C. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01310-w · Cited by 489
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Artificial intelligence as the next step towards precision pathology
Acs, B., Rantalainen, M., & Hartman, J. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13030 · Cited by 450
Wang, J., Li, D., Cang, H., & Guo, B. (2019) · Cancer Medicine · doi:10.1002/cam4.2327 · Cited by 349
Tumors induce de novo steroid biosynthesis in T cells to evade immunity
Mahata, B., Pramanik, J., van der Weyden, L., Polanski, K., Kar, G., Riedel, A., Chen, X., Fonseca, N. A., Kundu, K., Campos, L. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17339-6 · Cited by 326
O’Neil, B. H., Wallmark, J. M., Lorente, D., Elez, E., Raimbourg, J., Gomez-Roca, C., Ejadi, S., Piha-Paul, S. A., Stein, M. N., Abdul Razak, A. R., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189848 · Cited by 296
Denkert, C., Wienert, S., Poterie, A., Loibl, S., Budczies, J., Badve, S., Bago-Horvath, Z., Bane, A., Bedri, S., Brock, J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.109 · Cited by 285
The role of Nuclear Factor-kappa B signaling in human cervical cancer
Tilborghs, S., Corthouts, J., Verhoeven, Y., Arias, D., Rolfo, C., Trinh, X. B., & van Dam, P. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.001 · Cited by 269
Recent applications of immunomodulatory biomaterials for disease immunotherapy
Dai, H., Fan, Q., & Wang, C. (2022) · Exploration · doi:10.1002/exp.20210157 · Cited by 268
Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Mirlekar, B. (2022) · SAGE Open Medicine · doi:10.1177/20503121211069012 · Cited by 258
Identification of cancer driver genes based on nucleotide context
Dietlein, F., Weghorn, D., Taylor-Weiner, A., Richters, A., Reardon, B., Liu, D., Lander, E. S., Van Allen, E. M., & Sunyaev, S. R. (2020) · Nature Genetics · doi:10.1038/s41588-019-0572-y · Cited by 255
Lenalidomide enhances anti-myeloma cellular immunity
Luptakova, K., Rosenblatt, J., Glotzbecker, B., Mills, H., Stroopinsky, D., Kufe, T., Vasir, B., Arnason, J., Tzachanis, D., Zwicker, J. I., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1308-3 · Cited by 162
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Vrábel, D., Pour, L., & Ševčíková, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.003 · Cited by 123
Lindauer, A., Valiathan, C., Mehta, K., Sriram, V, de Greef, R., Elassaiss-Schaap, J., & de Alwis, D. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12130 · Cited by 120
Specific Immune Cell and Cytokine Characteristics of Human Testicular Germ Cell Neoplasia
Klein, B., Haggeney, T., Fietz, D., Indumathy, S., Loveland, K. L., Hedger, M., Kliesch, S., Weidner, W., Bergmann, M., & Schuppe, H.-C. (2016) · Human Reproduction · doi:10.1093/humrep/dew211 · Cited by 114
Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112
Metadata
- Authors
- Disis, M. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-10-10
- Volume
- 28
- Issue
- 29
- Pages
- 4531-4538
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138600064
- Cited by
- 489
- References
- 69
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.